Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from proprietary technology platforms, has received the final EUR6 million tranche of its financing agreement with the European Investment Bank (EIB).
The agreement originally was signed in February 2019 for a total of EUR15 million.
The loan is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the core of the Juncker Investment Plan for Europe, under which the EIB and the European Commission work together as strategic partners. The investment plan’s mission is to boost the competitiveness of the European economy and help promising small and midsize companies to grow.
